Severance for Small Cap Biotechs

posted in: Plan Design, Uncategorized | 0

We recently performed severance analyses for about 40 public companies with market caps below $1 billion. The group was mostly comprised of drug development companies without substantial revenues but there were a few device and service health care companies–also without … Continued